StockData
MediWound Ltd. logo

MediWound Ltd. (MDWD) stock

MDWDNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 5, 2026Score 2/30
$13.55+0.65 (+5.04%)

Close on Nov 16, 2026Market cap $173.92MP/E –Yield –

MediWound r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $14.32M, up 61.3% from the year before. Over ten years it grew 9.1% a year on average. The highest annual figure on record is $14.32M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$14.32M+61.3%
FY2024Dec 31, 2024$8.88M+18.9%
FY2023Dec 31, 2023$7.47M-26.7%
FY2022Dec 31, 2022$10.18M-0.7%
FY2021Dec 31, 2021$10.26M+33.2%
FY2020Dec 31, 2020$7.70M+54.9%
FY2019Dec 31, 2019$4.97M+22.0%
FY2018Dec 31, 2018$4.07M-25.4%
FY2017Dec 31, 2017$5.46M-22.7%
FY2016Dec 31, 2016$7.07M+17.4%
FY2015Dec 31, 2015$6.02M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.90M+169.3%
Q2 FY2025Jun 30, 2025$3.49M+31.4%
Q2 FY2024Jun 30, 2024$1.90M+17.7%
Q2 FY2023Jun 30, 2023$2.02M+1076.7%
Q2 FY2022Jun 30, 2022$2.19M+42.6%
Q2 FY2021Jun 30, 2021$2.66M+59.6%
Q2 FY2020Jun 30, 2020$1.61M–
Q2 FY2019Jun 30, 2019$172.00K–
Q2 FY2018Jun 30, 2018$1.54M–
Q2 FY2017Jun 30, 2017$1.66M–

More MediWound figures

See a number that looks wrong?